Who should not take Petrelintide?
Documented caution flags for Petrelintide include mTC / MEN-2 history and pancreatitis history. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Petrelintide is limited.
Documented caution flags for Petrelintide
- MTC / MEN-2 history
- Pancreatitis history
- Pregnancy / nursing
Reported side effects to weigh
- Mild nausea
- Reduced appetite
- Constipation
- Generally cleaner profile than GLP-1 monotherapy
References
- Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity — Zealand Pharma (press release via GlobeNewswire), March 5, 2026
- Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity — Roche (press release), March 5, 2026
- A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) — ClinicalTrials.gov, NCT06926842 (Sponsor: Zealand Pharma)
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Petrelintide
Last updated 2026-06-15.